Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | LY6K | Q17RY6 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585317 | 0.83 | CNR1 (0.45) | CNR2CNR1BRD4ALDH1A1ALDH3A1 | |
| SCHEMBL584385 | 0.81 | CNR2 (0.48) | CNR2CNR1BRD4ALDH1A1ALDH3A1 | |
| SCHEMBL584850 | 0.81 | PTGER4 (0.46) | PTGER4ALDH1A1 | |
| SCHEMBL13804940 | 0.79 | CNR1 (0.42) | CNR2CNR1PTGER4BRD4ALDH1A1 | |
| SCHEMBL3923613 | 0.79 | PTGER4 (0.47) | PTGER4ALDH1A1MAPTHPGDHTT | |
| SCHEMBL10048485 | 0.79 | PTGER4 (0.47) | PTGER4ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3765728 | 0.74 | PTGER4 (0.64) | CNR2PTGER4ALDH1A1MAPTHPGD | |
| SCHEMBL4968421 | 0.72 | NR1H3 (0.41) | PTGER4ALDH1A1LMNAHPGDHTT | |
| SCHEMBL584659 | 0.72 | PTGER4 (0.45) | PTGER4ALDH1A1MAPTHPGDHTT | |
| SCHEMBL27695223 | 0.72 | PTGER4 (0.45) | PTGER4ALDH1A1MAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797077-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| EP-1797077-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| CN-101052639-B | Benzimidazole derivatives, composition containing thereof, its preparation method and application | ASTRAZENECA AB SE | 2010-10-27 | — | — | CN | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-7550495-B2 | Compounds, compositions containing them, preparation thereof and uses thereof I | ASTRAZENECA AB (SE) | 2009-06-23 | — | — | US | disclosed |
| US-7550495-B2 | Compounds, compositions containing them, preparation thereof and uses thereof I | ASTRAZENECA AB (SE) | 2009-06-23 | — | — | US | disclosed |
| US-7550495-B2 | Compounds, compositions containing them, preparation thereof and uses thereof I | ASTRAZENECA AB (SE) | 2009-06-23 | — | — | US | disclosed |
| CN-101052639-A | Benzimidazole derivatives, composition containing thereof, its preparation method and application | ASTRAZENECA AB (SE) | 2007-10-10 | — | — | CN | disclosed |
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | CNR2 83/4885CNR1 54/4885PTGER4 102/4885 |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | CNR2 83/4885CNR1 54/4885PTGER4 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.